SCHEMBL3153786

SCHEMBL3153786

COc1cc2c(cc1OC)CCN(C(=O)CCN(C)CC1Cc3cc(OC(=O)N(C)C)ccc31)CC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.48
HTR1A P08908 1/20 0.48
SLC6A4 P31645 1/20 0.48
DRD3 P35462 1/20 0.48
KCNH2 Q12809 1/20 0.48
HCN4 Q9Y3Q4 1/20 0.48
KMT2A Q03164 4/20 0.45
ABCB1 P08183 1/20 0.39
ABCC1 P33527 1/20 0.39
MAPT P10636 4/20 0.39
MEN1 O00255 1/20 0.39
ACHE P22303 3/20 0.39
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
RAB9A P51151 1/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
BCHE P06276 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4242663 0.99 CHRM2 (0.47) CHRM2HTR1ASLC6A4DRD3KCNH2
SCHEMBL3150180 0.93 CHRM2 (0.48) CHRM2HTR1ASLC6A4DRD3KCNH2
SCHEMBL3143069 0.92 CHRM2 (0.46) CHRM2HTR1ASLC6A4DRD3KCNH2
Hydrochloric Acid SCHEMBL4247869 0.92 CHRM2 (0.47) CHRM2HTR1ASLC6A4DRD3KCNH2
Hydrochloric Acid SCHEMBL4247826 0.91 CHRM2 (0.45) CHRM2HTR1ASLC6A4DRD3KCNH2
SCHEMBL3155003 0.90 CHRM2 (0.47) CHRM2HTR1ASLC6A4DRD3KCNH2
SCHEMBL3155094 0.90 CHRM2 (0.47) CHRM2HTR1ASLC6A4DRD3KCNH2
Hydrochloric Acid SCHEMBL4253244 0.89 CHRM2 (0.46) CHRM2HTR1ASLC6A4DRD3KCNH2
SCHEMBL3149553 0.89 KMT2A (0.47) CHRM2HTR1ASLC6A4DRD3KCNH2
Hydrochloric Acid SCHEMBL4249161 0.89 CHRM2 (0.46) CHRM2HTR1ASLC6A4DRD3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076325-B2 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-12-13 US claimed
EP-2036892-B1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2010-03-10 EP claimed
WO-2009066041-A2 DERIVATIVES OF 1,2,4,5-TETRAHYDRO-3H-BENZAZEPINES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2009-05-28 WO claimed
EP-2036892-A1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2009-03-18 EP claimed
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-03-12 US claimed
US-8076325-B2 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-12-13 US disclosed
EP-2036892-B1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2010-03-10 EP disclosed
WO-2009066041-A2 DERIVATIVES OF 1,2,4,5-TETRAHYDRO-3H-BENZAZEPINES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2009-05-28 WO disclosed
EP-2036892-A1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2009-03-18 EP disclosed
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them OXER1, NR1H3, OXSR1 CHRM2 72/4885HTR1A 61/4885SLC6A4 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.